Alkem Laboratories

Alkem Laboratories

5,448.00
+54.50
(1.01%)
Market Cap
65,139.01 Cr
EPS
181.11
PE Ratio
28.38
Dividend Yield
0.83 %
Industry
Healthcare
52 Week High
6,439.90
52 Week Low
4,491.65
PB Ratio
5.38
Debt to Equity
0.13
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from18 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+38.89 %
+38.89 %
Hold
Hold+38.89 %
+38.89 %
Sell
Sell+22.22 %
+22.22 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,616.60
#1 3,87,876.49
33.67
#1 54,729.00
9.71
#1 10,980
-19.84
49.00
6,026.50
1,59,984.64
69.22
9,712.00
18.67
2,191
26.74
39.47
1,574.60
1,27,181.67
23.38
28,409.50
7.12
5,291
9.88
52.08
3,566.20
1,20,696.41
60.00
11,539.40
6.99
1,911
19.91
48.74
1,316.70
1,09,887.98
#1 19.15
33,741.20
16.73
5,725
1.26
60.35
2,579.60
1,06,467.51
56.70
12,744.20
#1 20.90
2,007
-18.14
58.41
1,044.75
1,05,126.30
22.52
23,511.00
18.55
4,615
2.60
68.18
2,043.40
93,321.15
24.55
22,909.50
13.74
3,306
#1 51.64
59.44
30,980.00
65,830.34
45.32
6,684.70
9.64
1,414
11.55
39.39
5,448.00
#10 65,139.01
#5 28.38
#6 13,458.30
#10 3.70
#6 2,216
#3 21.39
63.73
Forecast
Actual
Growth Rate
Revenue Growth
3.70 %
Net Income Growth
22.33 %
Cash Flow Change
-1.81 %
ROE
5.38 %
ROCE
4.61 %
EBITDA Margin (Avg.)
13.35 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
944
1,244
1,432
1,290
1,252
1,509
1,672
1,507
1,276
1,342
1,889
1,765
1,521
1,686
1,943
1,934
1,882
1,867
2,296
2,210
2,077
2,047
2,398
2,415
2,238
2,778
2,842
2,673
2,504
2,628
3,130
3,086
2,971
3,034
3,503
3,418
3,024
3,152
3,549
3,467
3,290
3,521
Expenses
777
1,001
1,127
1,052
993
1,210
1,328
1,214
1,102
1,218
1,405
1,381
1,389
1,455
1,555
1,613
1,619
1,585
1,811
1,729
1,746
1,470
1,762
1,789
1,901
2,139
2,176
2,121
2,162
2,373
2,626
2,442
2,652
2,579
2,751
2,668
2,546
2,423
2,662
2,615
2,753
2,632
EBITDA
167
242
306
238
260
299
344
294
174
124
485
384
132
231
388
321
263
282
484
481
331
577
636
626
337
640
666
552
343
255
505
644
319
455
752
750
478
729
887
852
537
889
Operating Profit %
13 %
16 %
17 %
17 %
14 %
18 %
19 %
18 %
12 %
7 %
24 %
21 %
7 %
12 %
19 %
16 %
13 %
14 %
20 %
21 %
15 %
26 %
25 %
23 %
13 %
22 %
22 %
19 %
13 %
8 %
15 %
20 %
9 %
13 %
20 %
20 %
13 %
20 %
22 %
23 %
12 %
22 %
Depreciation
18
21
26
23
24
23
26
26
26
31
35
38
40
43
46
48
57
56
56
60
81
67
70
69
69
71
73
78
83
76
77
78
78
72
74
70
83
81
79
85
113
88
Interest
17
23
20
19
10
10
12
12
11
13
18
15
10
16
16
15
7
16
18
17
14
17
18
13
11
13
12
11
17
27
25
27
29
30
30
26
27
29
28
36
28
30
Profit Before Tax
150
211
280
213
225
266
307
255
136
81
432
332
81
172
326
258
199
210
410
405
235
493
548
543
258
556
582
464
243
152
402
539
212
353
648
655
367
619
780
731
396
771
Tax
19
7
8
23
139
23
19
19
-1
17
105
152
15
35
66
53
28
23
29
15
44
70
66
80
9
76
23
-69
135
20
55
79
144
65
33
51
63
69
78
90
74
103
Net Profit
132
204
272
190
87
243
288
236
137
64
327
181
66
137
260
205
171
187
381
390
192
423
482
464
249
480
559
533
108
131
348
460
68
288
615
604
305
550
702
641
322
668
EPS in ₹
11.00
16.82
22.32
15.63
7.25
19.97
23.65
19.52
11.46
5.99
26.82
14.36
5.61
11.39
21.28
16.94
14.00
15.51
31.02
31.95
15.79
35.30
39.48
37.72
20.07
39.15
45.52
43.96
9.00
10.68
27.67
38.03
5.94
23.98
51.90
49.76
24.55
45.60
57.60
52.34
25.57
55.56

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
Current Assets
2,338
2,769
2,917
4,013
4,216
5,506
6,923
8,435
8,730
10,412
10,811
Capital Work in Progress
111
172
299
381
493
363
393
340
323
159
548
Investments
61
509
553
444
324
261
333
371
622
484
1,846
Other Assets
3,750
3,404
3,919
4,557
4,861
6,413
8,000
10,457
10,129
12,060
12,445
Total Liabilities
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Current Liabilities
2,006
1,538
1,690
2,383
2,218
3,245
3,604
4,805
3,707
3,995
3,959
Non Current Liabilities
205
210
296
297
419
392
357
417
615
866
1,299
Total Equity
3,085
3,787
4,583
4,985
5,572
6,309
7,558
8,847
9,435
10,714
12,434
Reserve & Surplus
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
Share Capital
24
24
24
24
24
24
24
24
24
24
24

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-208
-186
Investing Activities
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
-1,288
Operating Activities
326
726
471
266
780
585
1,265
1,111
1,683
1,948
1,913
Financing Activities
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
-811

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
60.16 %
58.84 %
58.84 %
57.13 %
57.13 %
57.14 %
57.16 %
57.16 %
57.16 %
57.16 %
56.74 %
56.74 %
56.74 %
56.38 %
55.66 %
55.66 %
55.13 %
53.04 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.11 %
8.69 %
9.02 %
10.15 %
9.41 %
9.11 %
DIIs
12.97 %
14.28 %
13.78 %
13.76 %
13.93 %
13.88 %
15.26 %
16.44 %
16.69 %
15.43 %
17.64 %
14.94 %
15.63 %
18.57 %
19.21 %
18.01 %
19.42 %
21.80 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
21.75 %
21.70 %
21.15 %
22.85 %
22.63 %
22.33 %
22.28 %
21.74 %
21.44 %
20.61 %
19.36 %
18.60 %
18.31 %
16.15 %
15.84 %
15.90 %
15.77 %
15.69 %
Others
5.12 %
5.17 %
6.23 %
6.26 %
6.31 %
6.65 %
5.30 %
4.67 %
4.71 %
6.80 %
6.26 %
9.72 %
0.21 %
0.21 %
0.26 %
0.28 %
0.28 %
0.36 %
No of Share Holders
92,594
93,540
87,392
86,881
81,869
84,104
79,721
76,516
73,440
66,790
69,442
65,184
65,830
69,627
74,744
84,038
84,326
79,740

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 15 13 16 25 30 34 50 40 45
Dividend Yield (%) 0.00 0.75 0.74 0.69 0.9 0.83 1.03 1.01 0.82 0.83

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Feb 2021 DIVIDEND Dividend
₹ 25.00 /share
11 Feb 2021 2,975.90 2,868.65
10 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
09 Aug 2021 2,996.15 3,514.65
12 Feb 2022 DIVIDEND Dividend
₹ 30.00 /share
10 Feb 2022 3,537.95 3,431.45
10 Aug 2022 DIVIDEND Dividend
₹ 4.00 /share
08 Aug 2022 2,960.40 2,985.40
18 Feb 2023 DIVIDEND Dividend
₹ 25.00 /share
17 Feb 2023 3,230.05 3,264.35
18 Feb 2023 DIVIDEND Dividend
₹ 15.00 /share
17 Feb 2023 3,230.05 3,264.35
10 Aug 2023 DIVIDEND Dividend
₹ 10.00 /share
10 Aug 2023 3,326.30 4,227.25
17 Feb 2024 DIVIDEND Dividend
₹ 35.00 /share
16 Feb 2024 5,309.25 5,444.15
10 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
09 Aug 2024 5,314.35 5,793.15
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Aug 2024 5,314.35 5,998.65
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 5,796.25 5,501.35
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Feb 2025 4,954.15 5,256.60
14 Feb 2025 DIVIDEND Dividend
₹ 37.00 /share
14 Feb 2025 5,256.60 4,722.30
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 5,290.35 5,265.65
08 Aug 2025 DIVIDEND Dividend
₹ 8.00 /share
08 Aug 2025 5,265.65 4,878.10
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 4,894.80 4,842.40
25 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
25 Aug 2025 5,265.65 5,425.80

Announcements

Announcement Under Reg 30 (LODR)- Cancellation Of Analyst / Institutional Investor Meeting Scheduled On Tuesday 09Th September 2025.4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 25, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Closure of Trading WindowAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionAug 12, 2025
Results- Unaudited Financial Results For Quarter Ended June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of The BM Dated 12Th Aug 2025Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On 12Th August 2025.Aug 04, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotAug 04, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 04, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderJul 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 21, 2025
Notice Of 51St Annual General Meeting And Annual Report For FY 2024-25Jul 21, 2025
Reg. 34 (1) Annual Report.Jul 21, 2025
Approval For Reclassification Under Regulation 31A Of SEBI LODR Regulations 2015Jul 16, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 14, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJul 03, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 24, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 23, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 18, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderJun 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 13, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 06, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderJun 06, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 29, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Closure of Trading WindowMay 29, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2025

Technical Indicators

RSI(14)
Neutral
67.21
ATR(14)
Less Volatile
95.65
STOCH(9,6)
Neutral
66.53
STOCH RSI(14)
Neutral
55.33
MACD(12,26)
Bearish
-5.62
ADX(14)
Weak Trend
19.36
UO(9)
Bearish
45.45
ROC(12)
Uptrend And Accelerating
0.48
WillR(14)
Overbought
-9.65

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Value Direct-Growth
0.18%
-235420
-0.21%
-0.20%
ICICI Prudential India Opportunities Fund Direct - Growth
1.01%
-132716
-0.18%
-0.17%
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
3.04%
-125454
-0.17%
-0.17%
Bandhan Large & Mid Cap Fund Direct-Growth
0.87%
57727
0.31%
0.46%
Sundaram Value Fund Direct-Growth
1.98%
54500
1.98%
1.98%
ICICI Prudential Equity Arbitrage Direct-Growth
0.10%
53750
0.09%
0.09%
Tata Arbitrage Fund Direct - Growth
0.26%
51375
0.14%
0.18%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.64%
43175
0.64%
0.64%
ICICI Prudential Multicap Fund Direct Plan-Growth
1.41%
-42529
-0.04%
-0.02%
Invesco India Arbitrage Fund Direct-Growth
0.36%
42250
0.10%
0.10%
Kotak Arbitrage Fund Direct-Growth
0.34%
37375
0.04%
0.13%
ICICI Prudential Innovation Fund Direct - Growth
1.32%
-30000
-0.16%
-0.13%
HDFC Pharma And Healthcare Fund Direct - Growth
3.94%
26500
0.95%
0.76%
Mirae Asset Arbitrage Fund Direct - Growth
0.61%
25500
0.48%
0.50%
ICICI Prudential Bharat Consumption Fund Direct - Growth
0.26%
-22000
-0.34%
-0.33%
Bandhan Multi-Factor Fund Direct - Growth
2.06%
19586
2.06%
2.06%
UTI Healthcare Fund Direct-Growth
3.41%
17000
1.00%
1.30%
LIC MF Large Cap Fund Direct-Growth
0.63%
-16785
-0.54%
-0.48%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.39%
16638
0.39%
0.39%
LIC MF Flexi Cap Fund Direct-Growth
0.00%
-16311
-0.80%
-0.79%
Axis Arbitrage Fund Direct-Growth
0.25%
16125
0.11%
0.13%
LIC MF Balanced Advantage Fund Direct - Growth
0.00%
-13790
-0.84%
-0.81%
ICICI Prudential Regular Savings Fund Direct-Growth
0.28%
-12469
-0.18%
-0.17%
Edelweiss Arbitrage Fund Direct-Growth
0.08%
12375
0.04%
0.06%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.06%
11125
0.03%
0.03%

About Alkem Laboratories

Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than 40 international markets, with the United States as its key focus. Alkem is ranked the fifth largest pharmaceutical company in India by domestic sales. The company's product offerings span various therapeutic areas such as anti-infective, cardiology, neurology, and gastroenterology. Alkem has invested in research and development, filing numerous Abbreviated New Drug Applications (ANDAs) with the US FDA. The company has multiple manufacturing facilities in India and abroad, and has expanded through acquisitions and subsidiaries in different countries.
Listing Date
23 Dec, 2015(9 Years, 21 days)
Chairperson NameBasudeo N Singh